



FOR IMMEDIATE RELEASE

Ohmx Corporation Contacts:

Erin Tower
Tel: (847) 491-4401
Fax: (847) 491-8510
erin@ohmx.com

Ohmx Corporation granted another patent

Evanston IL, May 27th 2014 – Ohmx Corporation, an In-Vitro Diagnostics company developing the only comprehensive POC platform able to detect proteins, DNA, and small molecules, is pleased to announce that another patent application from its portfolio has been granted.

Since its founding, Ohmx has developed a number of innovative technologies with practical applications to many of today’s healthcare diagnostics settings. Ohmx’s focus is on decentralizing healthcare and expanding near patient testing capabilities by providing a POC diagnostic system with performance comparable to central labs. Such performance is made possible by the unique features of Ohmx’s proprietary bioelectronic platform technology. Ohmx has patented new methods and materials that interact with its electrodes to perform a wide range of clinical assays (immunoassays, small molecule assays, or molecular assays). The versatile bioelectronic platform rapidly generates signal across a broad dynamic range, with self calibrating raw data that provides fully quantitative results. The Ohmx platform requires only a minimal sample volume (1-50 uL), offers ultrasensitive detection capability, accurate and precise assays, and performance level similar to reference lab tests.

The latest patent added to Ohmx’s patent portfolio is:
Novel Chemistry Used in BiosensorsUS Patent Number 8,734,631

When asked about this exciting milestone, Ohmx’s founder Prof. Thomas Meade said “Intellectual Property is incredibly important to young companies, especially while new technologies are being developed. It is highly rewarding that Ohmx’s original techniques are now patented in countries all over the world.”

Other granted patents that have already been issued by the patent offices of the United States, Europe, and Japan include:

U.S. Patent.....8,530,170
European Patent (Ratified in 6 European countries).....2,462,238
Japanese Patent.....5,352,742

Beyond the patents already granted, Ohmx also has more published patent applications and undisclosed applications pending world-wide.

About the Company:

Ohmx is an In-Vitro Diagnostics company that is developing a reliable, low-cost, comprehensive, point-of-care (POC) system that quantifies analytes from low-volume biological samples (e.g. whole blood, urine, semen, prostatic fluid, saliva etc). Ohmx’s

market entry strategy is based on a portable blood analyzer to assist clinicians with screening, diagnosis, and monitoring of patients with chronic or acute diseases in the Physician Office Lab (POL) and Emergency Department (ED) settings respectively. The Ohmx POC device will also enable doctors to quickly and cost-effectively screen and manage preventive medicine for patients, in an effort to reduce the unsustainable inflation of healthcare costs. It is the only POC system that can provide quantitative analysis of proteins, small molecules, and DNA tests on one platform.

This press release contains forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from the results identified or implied in any forward-looking statement. These statements are based on our views as of the date they are made with respect to future results or events. The Company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results or events expressed or implied therein will not be realized.